Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Autoimmune Disorders01:29

Autoimmune Disorders

417
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
417
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

European journal of neurology·2026
Same author

Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

Neurology·2026
Same author

Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis.

Journal of neurology·2026
Same author

No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy.

Journal of the neurological sciences·2026
Same author

Prescriptions and healthcare use in multiple sclerosis patients within general practices in the Netherlands.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: Jun 26, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

[Treatment of multiple sclerosis].

Nandi Meijs1,2, Brigit A De Jong3, Bob W Van Oosten3

  • 1Zuyderland Medisch Centrum, afd. Neurologie, Sittard/Heerlen.

Nederlands Tijdschrift Voor Geneeskunde
|May 15, 2024
PubMed
Summary

Multiple sclerosis (MS) management is complex, especially with co-occurring autoimmune diseases. This case study highlights challenges and opportunities in selecting effective MS treatments when patients also have conditions like Crohn's disease.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K

Related Experiment Videos

Last Updated: Jun 26, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Clinical Neurology

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease driven by autoimmunity.
  • Therapeutic options for MS have significantly expanded.
  • Managing MS in patients with other autoimmune conditions presents unique clinical considerations.

Purpose of the Study:

  • To present two distinct clinical cases of multiple sclerosis.
  • To illustrate the complexities of MS treatment in the context of concurrent autoimmune disorders.
  • To explore treatment strategies when multiple autoimmune diseases are present.

Main Methods:

  • Case report presentation of two patients with multiple sclerosis.
  • Review of treatment responses and disease course.
  • Analysis of therapeutic implications of co-existing autoimmune conditions.

Main Results:

  • Patient A demonstrated a relapsing-remitting MS course effectively managed with second-line therapy.
  • Patient B experienced a new MS relapse following the initiation of TNF-alpha blockade for Crohn's disease.
  • The interplay between different autoimmune diseases impacts treatment decisions.

Conclusions:

  • Co-occurrence of autoimmune diseases like MS and Crohn's disease complicates therapeutic choices.
  • Careful consideration of treatment interactions is crucial for optimizing patient outcomes.
  • Concurrent autoimmune conditions offer opportunities for tailored and potentially synergistic treatment strategies.